CORRECTING and REPLACING CytoDyn Relocates Offices to Accommodate Expanded Activities

SANTA FE, N.M.--(BUSINESS WIRE)--First graph, second sentence of release dated October 7, 2008 should read: CytoDyn’s phone number will remain 505-988-5520, the Company’s original number (sted: The Company’s new phone number is 505-412-6480). Also please note the contact phone number for Corinne Allen should read: 505-577-1636 (sted: 505-412-6480).

The corrected release reads:

CYTODYN RELOCATES OFFICES TO ACCOMMODATE EXPANDED ACTIVITIES

CytoDyn, Inc. (Pink Sheets:CYDY) has relocated its business offices to 1511 Third Street, Santa Fe, NM 87505. CytoDyn’s phone number will remain 505-988-5520, the Company’s original number. The FAX number remains the same: 800-417-7252. The expanded office space will accommodate the staff needed to bring CytoDyn’s periodic filings up to date. Pender, Newkirk & Company, LLP of Tampa, FL continues to serve as the Company’s auditors.

In addition to becoming current in its filings, CytoDyn anticipates the next clinical trial of Cytolin®, the Company’s first-in-class drug for treating HIV/AIDS. The study will be conducted by prominent AIDS researcher Dr. Jay Lalezari in San Francisco, California with GMP product manufactured in San Diego, California. The study will be managed by Target Health, Inc. of New York, NY, which the Company has retained to serve as its Contract Research Organization (CRO).

CytoDyn is also pleased to announce that Parviz Lalezari, M.D., a prominent immunohematologist at the Montefiore Medical Center in New York, has joined the Company’s Scientific Advisory Board.

This press release contains forward-looking statements that are not historical facts. CytoDyn’s management makes forward-looking statements concerning the Company's expected future operations, performance and other developments. These forward-looking statements are necessarily estimates based upon current information and projections and involve a number of risks and uncertainties, including but not limited to, the failure of preliminary results from clinical studies to reflect the results from more comprehensive studies. There can be no assurance that such risks and uncertainties, or other factors, will not affect the accuracy of such forward-looking statements. It is impossible to identify all the factors that could cause actual results to differ materially from those estimated by CytoDyn. They include, but are not limited to, government regulation, managing and maintaining growth, victimization by white-collar offenders, and the effects of adverse publicity, litigation, competition, and other factors that may be identified from time to time in the Company's announcements.

CytoDyn, Inc.
Corinne Allen, 505-577-1636